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creativecommons.org/licenses/by-nc-nd/4.0/A B S T R A C TKeywords: There are notable differences betweenAsians andWesterners regarding hypertension (HTN) and
the relationship between HTN and cardiovascular disease (CVD). Asians show greater morning
surges in blood pressure (BP) and a steeper slope illustrating the link between higher BP and the
risk of CVD events. It is thus particularly important for Asian hypertensives to achieve 24-h BP
control, including morning and night-time control. There are three components of ‘perfect 24-h
BP control:’ the 24-h BP level, nocturnal BP dipping, and BP variability (BPV), such as themorning
BP surge that can be assessed by ambulatory BP monitoring. The morning BP-guided approach
using home BPmonitoring (HBPM) is the first step toward perfect 24-h BP control, followed by the
control of nocturnal HTN. We have been developing new HBPM devices that can measure
nocturnal BP. BPV includes different time-phase variability from the shortest beat-by-beat,
positional, diurnal, day-by-day, visit-to-visit, seasonal, and yearly changes. The synergistic
resonance of each type of BPV would produce a great dynamic BP surge (resonance hypothesis),
which triggers a CVD event, especially in the high-risk patients with systemic hemodynamic
atherothrombotic syndrome (SHATS). In the future, the innovativemanagement ofHTNbasedon
the simultaneous assessment of the resonance of all of the BPV phenotypes using a beat by beat
wearable ‘surge’ BPmonitoring device (WSP) and an information and communication technology
(ICT)-based data analysis system will produce a paradigm shift from ‘dots’ BP management to
‘seamless’ ultimate individualized ‘anticipationmedication’ for reaching a zero CVD event rate.
© 2016 The Author. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Morning hypertension
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tension (HTN) is one
of the most widespread
andpowerful riskfactors
for these diseases, and
its role in global health
and that of the Japanese
is of great interest.1
There are signifi-
cant ethnic differences
in the characteristics of
HTN and CVD (Fig 1).2,3
In Asian countries (e.g.,
Japan, China, Korea,
Taiwan), the association of
HTN and CVD is stronger
than inWestern countries
(e.g., Europe and the U.S.).
In Asians, stroke is more
common than coro-
nary heart disease (CHD),
whereas in Westerners
CHD is more common
than stroke.4 Hemor-
rhagic stroke in partic-
ular is more common
inAsians than inWest-
erners, among both in-
dividualsmedicatedwith
anticoagulation therapy
and those without such
therapy.
In the series of
medicated HTN pa-
tients enrolled in arecent nationwide prospective study, the Home Blood Pressure
Measurement With Olmesartan-Naive Patients to Establish
Standard Target Blood Pressure (HONEST) study, the incidence
of CVD events (i.e., stroke, myocardial infarction/MI, angina
pectoris with intervention, and sudden cardiac death/SCD) was
6.46 per 1000 person-years, and the incidence of stroke was
three timeshigher than that ofMI.5When angina pectoris andMI
were combined as ‘CHD,’ the incidence of CHD was comparable
to that of stroke.5 The association slope of the blood pressure
(BP) level against the risk of CVD events, especially stroke, is
significantly steeper in Asians than inWesterners.6
Excess salt intake in combinationwithhigher salt sensitivity
is an important environmental risk for the predisposition to
essential HTN. In addition to higher salt intake, salt sensitivity
is genetically greater in Asian populations than Western
populations. The gene frequency of candidate gene polymor-
phisms of salt-sensitive HTN such as angiotensinogen gene,
alpha-adducin gene, promoter of the aldosterone synthase
gene, G-protein beta3 subunit gene (GNB3), etc. was significant-
ly higher in several Japanese populations than in Caucasians,
indicating the enormous interracial differences in the frequen-
cy of salt-sensitive hypertension.7
The prevalences of obesity and related metabolic syn-
drome are now dramatically increasing in Asian countries.Obesity increases sympathetic activity and salt sensitivity.
Obese Asians may be more prone to develop HTN compared
to obese Caucasians. With even a mild increase in body mass
index (BMI), the prevalence of preHTN increases in younger
Asian adults. In fact, in our long-term population-based
cohort (the Jichi Medical School (JMS) Cohort study), the
subjects with a mild increase in BMI (23.0–24.9 kg/m2) had an
increased risk of preHTN,8 which is associated with an
increased 10-year risk of CVD, and this risk may be elevated
during the second 5-year period in the nonelderly.9 In
addition, a recent international comparison study demon-
strated that the Japanese HTN patients had significantly
higher morning BP levels and morning BP surges than Italian
and Spanish patients matched for age and office BP level.10
Although HTN is a great burden on healthcare globally, the
country-based regional approach considering ethnic differ-
ences in the pathogenesis and clinical characteristics of HTN
is important for effective practical management.11 Consider-
ing the above-described Asian characteristics, the benefit of
antiHTN medication would be greater in Asians and in
Westerners, especially for stroke and HF. A meta-analysis of
subjectswith type 2diabetes (T2D) and/or impaired fasting glucose
demonstrated that more-intensive BP control (≤130 mmHg) was
associated with a greater reduction in stroke, and that controlling
BP to a systolic BP (SBP) of <120 mmHg resulted in continued risk
reduction for stroke, although it didnot reduceotherCVDevents.12
The Japanese guidelines (JSH2014G) thus retain the target
BP <130/80 mmHg for diabetic HTN patients,1 whereas many
international guidelines increased the target BP level of diabetic
HTN patients.13,14 The acquisition of global comparative
evidence of the efficacy of different drugs could contribute to
the development of country-based regional specific guidelines
for the management of HTN.Evidence of benefit of strict BP control
A recently published paper from the Systolic Blood Pressure
Intervention Trial (SPRINT)15 has triggered a discussion of
some of the most important clinical topic: which BP level
should be targeted as the treatment of HTN. Several interna-
tional guidelines have been published recently that, compared
with theprevious guidelines, increased the target BP levels from
130/80 mmHg to 140/90 mmHg for high-risk patients with T2D
and/or CKD and from140/90 mmHg to 150/90 mmHg for elderly
HTN patients.13,14 However, at the end of 2015, strikingly
opposing results from the SPRINT study were published.
In SPRINT, over 9000 patients with SBP >130 mmHg and an
increased CVD risk (except T2D) were randomly assigned to a
strict-control group (target SBP<120 mmHg) or standard-
control group (<140 mmHg).15 After a median follow-up of
3.26 years, the strict-control group, as compared with the
standard-control group, had a 25% lower relative risks of
major CVD events and 27% lower relative risks of death from
any cause, but the rates of some serious adverse events –
including hypotension and acute kidney injury or failure –
were significantly higher in the strict-control group than in
the standard-control group.
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stroke, in light of the results of two trials that included these
high-risk subgroups. In the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) Trial examining diabetic hyperten-
sive patients, therewasno significant benefit of strict BP control
at <120 mmHg compared to routine BP control at <140 mmHg
for the suppression of the composite endpoints of CHD, stroke,
and CVD death.16 However, in this trial, the strict BP control
significantly reduced stroke events (one of the secondary
endpoints) by 40% compared to the standard control (p = 0.01).
The effects of the strict BP control on individual outcomes in
SPRINT and the ACCORD trial are generally consistent, sug-
gesting that this strict BP control is superior for high-risk HTN
patients, including diabetic HTN. In another randomized
open-label trial, the Secondary Prevention of Small Subcortical
Strokes (SPS3) study, patients with recent symptomatic lacunar
infarctions were randomly assigned to a higher-target or lower-
target BP group according to a SBP target of 130–149 mmHg
or <130 mmHg, respectively. During the mean 3.7-year follow-up,
non-significant difference in rate reductions between the 2 groups
was seen for the primary endpoint, i.e., all stroke (hazard ratio 0.81,
p = 0.08), but the rate of intracerebral hemorrhage was significantly
reduced in the lower-target group than in the higher-target group
(0.37, p = 0.03).17
In addition, a 2015 meta-analysis of over 613,000 HTN
patients from randomized controlled trials clearly demon-
strated that antiHTN medication reduced the rates of all CVD
events and death in all patients, including those with SBP
<130 mmHg, regardless of concomitant diseases.18 This
benefit was especially stronger for stroke and HF.18 These
results support the benefit of more strict BP control to at least
<130 mmHg, not only in the SPRINT high-risk group but also
in other high-risk groups. Thus, the guidelines for the
management of HTN should modify the target BP level before
the regularly scheduled revisions are conducted.11Importance of ‘24-h BP control’
In my research group, we define the status of ‘perfect 24-h BP
control,’ which minimizes the organ damage and risk of CVD
events, as the achievement of the following three compo-
nents: (1) the average of 24-h BP levels is <130/80 mmHg, (2) a
normal circadian rhythm, i.e., adequate dipping of nocturnalFig 1 – Characteristics of hypertension in Asian populations
(i.e., Japan, China, Korea, Taiwan, etc.). (Modified from Ref. 2).BP (dipper-type) is observed, and (3) adequate BP variability (BPV)
(e.g., morning BP surge <45 mmHg) is achieved (Fig 2).19 The first
component concerns the quantity of BP control, and the latter
two components focus on the quality of BP control. In clinical
practice, beyond the goal of strict office BP control, the three BP
profiles of white-coat effect, BPV, and nocturnal BP should also
be considered.
White-coat effect
It is important to exclude the white-coat effect on office BP to
assess the remaining BP overload to the cardiovascular (CV)
system and to avoid a harmful excessive BP reduction by
antiHTN medication. There are three different BP measure-
ments which can exclude the white-coat effect in the current
clinical practice.
The first is the gold standard, i.e., ambulatory BP monitor-
ing (ABPM).19–24 The 24-h BP (that is, the average of BPs) is
more closely associated with HTN organ damage and the risk
of future CVD events than office BP is among both
community-dwelling populations and HTN patients. The
24-h SBP in particular is more important as a risk factor for
CVD events in the elderly than 24-h diastolic BP,22 In our
prospective study, the Jichi Medical University ABPM
(JMU-ABPM) study of elderly HTN, a 10-mmHg increase
accounted for a 38% increase in the risk of CVD events.22
ABPM is used in the definitions of 24-h HTN, i.e., 24-h BP (the
average of 24-h BPs) values ≥130/80 mmHg; daytime HTN, i.e.,
daytime BP (the average of daytime BPs) ≥135/85 mmHg, and
nocturnal HTN, i.e., nocturnal BP (the average of nocturnal
BPs) ≥120/70 mmHg, regardless of office BP values.White-coat
HTN (i.e., HTN for office BP, and normotension for 24-h BP) is
at lower risk during the short-term period,22,24 but it may
deteriorate to sustained HTN and diabetes, resulting in an
increased risk of future CVD events.23 On the other hand, the
CVD risk in untreated masked HTN (normotension for office
BP, and HTN for 24-h BP) is similar to that from sustained
HTN.24 Thus, masked HTN should be regarded as a subtype of
HTN, which should be treated.
The second type of BPmeasurement is automated office BP
(AOBP) monitoring, which automatically measures an
individual's BP while he or she is seated in a quiet room
without the presence of medical staff. The SBP values that are
obtained by AOBP are lower by 5–10 mmHg and the risk of
future CVD events than standard doctor-measured office BP
values.25 The threshold of the diagnosis of HTN based on
AOBP monitoring is 135/85 mmHg.25 In the SPRINT, the office
BP values were obtained by AOBP, not doctor-measured.
The third type of BP measurement is self-measured BP using
HBPM,26 and home BP measured in the morning (morning BP) is
especially important.19 In our prospective HONEST study using
HBPMconductedbyover 21,000HTNpatients,whenhomemorning
SBP was well-controlled at <125 mmHg during a follow-up, there
wasno increase inCVDeventsevenamongtheHTNpatientswhose
office SBP remainedat ≥150 mmHg.5On theother hand, evenwhen
office SBP was well controlled at <130 mmHg, the hazard ratio of
CVD events was 2.5 in the masked uncontrolled HTN group with
morning SBP ≥145 mmHg compared to the well-controlled groups
with morning SBP <125 mmHg. Morning home BP is a strong
Fig 2 – The triad of perfect 24-h blood pressure control. BP, blood pressure. (Modified from Ref. 19 ).
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superior to clinic BP in this regard.27 In addition, there does not
appear tobea J-curve in the relationshipbetweenmorninghomeBP
and CVD events. The Hypertension Objective Treatment Based on
Measurement by Electrical Devices of Blood Pressure (HOMED-BP)
studydemonstrated that the 5-year riskofCVDeventswasminimal
when the on-treatment home SBPwas <132 mmHg.28
Although there is no consensus about the optimal target
BP level, it may be recommended that these white-coat
effect-excluded BP measurements should use <125 mmHg as
the target, with the corresponding value of doctor-measured
office SBP of 130 mmHg (Fig 3).11
Based on the findings of the HONEST study, we are now
proposing the 3-step strategy of morning BP-guided manage-
ment of HTN using HBPM (Fig 4).19 The HONEST study
revealed 144 mmHg as the threshold of on-treatment morn-
ing BP for a significant increase in CVD events, and approx.
125 mmHg as the minimum risk.5 In addition, there was no
J-curve until approx. 100 mmHg of morning SBP. Thus, as
the first step, morning SBP should be treated using the
target <145 mmHg for all HTN patients, and the second step
is the guideline level, 135 mmHg. Approximately ≤125 mmHg
presents the lowest risk of CVD events.
Morning BP (morning BP surge)
Morning SBP parameters are defined as follows. ‘Morning BP’
is the average of morning BP values during the first 2 h after
arising or between 7 a.m. and 9 a.m. The ‘moving peak
morning BP’ is defined as the highest 1-h moving average of
consecutive BP values (3 points) during the first 2 h after
arising, or between 6 a.m. and 10 a.m. The ‘maximum
morning BP’ is the maximum morning BP value [a single BP
value] during the first 3 h after arising or between 7 a.m. and
10 a.m.19 The ‘prewakening nocturnal BP’ or ‘minimal (or
moving prewakening) morning BP’ between 5 a.m. and 9 a.m.
is used to calculate the prewakening morning BP surge. Thedefinition of morning HTN is morning BP ≥135/85 mmHg
regardless of office BP.19,29,30 In elderly HTN patients, morning
HTN, defined as morning BP ≥135/85 mmHg is most closely
associatedwith CVD events among the office and ambulatory BP
values measure during different time periods of the 24-h day.30
Controlling morning BP is the important first step of
‘perfect 24-h BP control’ in medicated HTN patients, because
the risk of CVD events is the highest and the BP-lowering
effect of conventional antiHTN drugs is the weakest in the
morning.19,29 Morning BP is more closely related to sympa-
thetic nervous activity, and thus the bedtime dosing of
alpha-blockers, doxazosin, and catheter-based renal dener-
vation is effective for reducing morning BP.31,32
Morning BP surge parameters can be calculated as
follows.19 The ‘sleep-trough morning surge’ is calculated as
the average morning BP value minus the moving lowest
nocturnal BP value. The ‘prewakening morning surge’ is
calculated as the average morning BP value minus the
prewakening morning BP value. In our JMU-ABPM study, the
ABPM-defined morning surge in SBP (sleep-through morning
surge, and prewakening morning surge) was associated with
MRI-detected silent cerebral infarcts and future clinical stroke
events, independently of 24-h SBP and nocturnal BP dipping
status (Fig 5).33–36 As an adequate morning BP surge is
physiological, the exaggerated morning BP surge above some
threshold (e.g., the top 10th percentile of the study subjects)
should be considered pathological. Asians are likely to have a
higher degree of morning BP surge than Westerners.10
Nocturnal BP (nighttime BP) and dipping
Nocturnal BP parameters are defined as follows.19 ‘Nocturnal
BP’ is the average of nocturnal BP values. The ‘average peak
nocturnal BP’ is the average of the three highest different
nocturnal BP values. The ‘maximum nocturnal BP’ is the
single peak BP value. The ‘minimum nocturnal BP’ is the
single lowest BP value. The ‘moving lowest nocturnal BP’ is
Fig 3 – Precision medication for the management of hypertension. The strict BP control (quantity of BP control) guided by
white-coat effect-excluded BP <125 mmHg, as well as office BP <130 mmHg for all hypertensive patients. ‘Perfect 24-h BP
control’ considering BP variability and nocturnal hypertension (quality of BP control) is recommended for high-risk patients
with hypertension. The CCBs and ARBs may be protective against stroke by reducing BP variability, and drugs that reduce
circulating volume such as diuretics, LCZ696, and SGLT2 inhibitors may be protective against heart failure by reducing
nocturnal BP. SBP, systolic BP; SGLT2, Sodium-glucose co-transporter 2. (Modified from Ref. 11).
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values. The ‘prewakening nocturnal BP’ is the average of
nocturnal BPs during the 2 h before arising. The definition of
nocturnal HTN is nocturnal BP ≥120/70 mmHg, regardless of
office, daytime and/or morning BP values.1,19
Nocturnal HTN is a risk factor for damage to the brain,
heart, kidney, and large and small arteries and for all the CVD
events including both hemorrhagic and ischemic stroke, CHD,
HF (especially with preserved ejection fraction/HFpEF), CKD,
and SCD, independently of office BPs, in both community-
dwelling populations and HTN patients.37–40 Nocturnal HTN is
also associated with brain MRI-evaluated brain atrophy andFig 4 – Home blood pressure-guided three-step antihypertensivesilent cerebral disease, and physical and cognitive dysfunc-
tion in the elderly.19 Even among completely normotensive
community-dwelling subjects, those with isolated nocturnal
HTN are likely to have LVH, especially concentric LVH, and to
have increased plasma levels of atrial natriuretic peptide and
B-type natriuretic peptide (BNP).38 In both medicated or
non-medicated individuals, masked uncontrolled nocturnal
HTN with well-controlled office, home and/or daytime BP is
associated with increases in arterial stiffness, the plasma
level of BNP and the urinary albumin/excretion ratio,40
suggesting that nocturnal HTN is an independent risk for
future CVD events. Nocturnal BP is preferentially reduced bystrategy for morning hypertension. (Modified from Ref. 19 ).
Fig 5 – Prevalence of MRI-detected silent cerebral infarcts and incidence of stroke events over a 42-month period in elderly
hypertensive patients with or without morning surge in blood pressure: the Jichi Medical University ABPM study, Wave 1.
*matching for age and 24-h systolic blood pressure (Modified from Ref. 33).
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ute to nocturnal HTN.41,42 Renal denervation also significantly
reduced nocturnal BP, indicating that sympathetic nervous
activity may partly determine nocturnal BP by reducing
sodium excretion and increasing peripheral vascular resistance.32
The average peak and the maximum nocturnal BP values may be
related to the nocturnal BP surge triggered by apnea/hypopnea
episodes of obstructive sleep apnea (OSA),43,44 and the moving
lowest andminimumnocturnal BP valuesmay be related to the
circulating volume and/or vascular structure (both large and
small arteries).19
Nocturnal BP dipping parameters can be calculated as
follows. ‘Nocturnal BP dipping (%)’ is calculated as: (1 − the
average nocturnal BP/average daytime BP) × 100. Based on the
nocturnal dipping of SBP, the following subgroup classification:
extreme dipper: >20%; dipper: ≤20%, >10%; non‐dipper: ≤10%,
>0%; riser: ≤0%. The non-dippers and riser classifications are
associated with organ damage of the brain, heart and kidney
and future CVD events in both younger normotensives and
older HTN.45–52 Among patients with HF, the riser pattern is
more common in HFpEF than in those with reduced ejection,
and the riser pattern is associated with mild cognitive
impairment.51,52 Even among community-dwelling normoten-
sive subjects, non-dippers have advanced LVH, especially
concentric LVH,47 and poor CV prognoses.48
Extreme-dipping, another extreme edge of disrupted
circadian BP rhythm, may be associated with silent cerebral
disease and nonfatal stroke in elderly HTN patients.45,46
Our JMU ABPM study was the first to demonstrate that
extreme-dippers had advanced silent cerebral infarcts and
white matter lesions, detected by brain MRI at the baseline,
and an increased risk of future stroke during a follow-up,
compared to normal dippers.45,46 Young normotensive subjects
who exhibited either the extreme-dipper or riser patterns at the
baseline developed advance coronary calcium evaluated bycomputed tomography performed in their middle aged adults
10 years or more after the baseline ABPM.50 In the Ambulatory
Blood Pressure Collaboration in Patients with Hypertension
(ABC-H) meta-analysis of 17,312 with HTN from three conti-
nents, the extreme-dippers' risk of CVD events was markedly
modified by the treatment status. Extreme dipping relative to
normal dipping carried a borderline reduced risk of CVD events
(HR: 0.72; p = 0.050), whereas among cohorts of untreated
patients, extreme dipping was hazardous (HR: 1.92; p = 0.006).53
Therefore, disrupted diurnal variations (i.e., the extreme dipper
and riser patterns) are risk factors for CVD, independently of
24-h BP.
Nocturnal BP surge parameters can be calculated as
follows. The ‘average nocturnal surge’ is calculated as the
average peak nocturnal SBP minus the average nocturnal SBP.
The ‘dynamic nocturnal surge’ is the average peak nocturnal
SBP minus the moving lowest nocturnal SBP. The ‘maximum
dynamic nocturnal surge’ is defined as the maximum
nocturnal SBP minus the minimum nocturnal SBP. An
increase in the standard deviation (SD) of nocturnal BP values,
one of the measures of nocturnal BPV, is associated with CVD
events independently of the average of nocturnal BPs. The
cut-off value of the pathological SD was 12.2 mmHg.54 In
addition, in HTN patients there is a synergistic increase in the
CV risk with the combination of non-dipping of both the
nocturnal BP and the heart rate. The nocturnal BP-non-
dippers with the nocturnal heart rate non-dipper pattern
exhibited worse CV prognoses.55AntiHTN medication considering
24-h BP variability
The morning BP-guided approach using HBPM is the first step
toward perfect 24-h BP control.19,29 After controlling morning
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meta-analysis of the randomized controlled trials of antiHTN
medication revealed that among high-risk HTN patients (who
are prone to stroke and HF), different classes of antiHTN drugs
had different BP-lowering effects; calcium channel blockers
(CCBs) were more effective for reducing stroke, and diuretics
were more effective for reducing HF.18 These findings may
partly be explained by the different BP-lowering profile of each
class of drugs. The CCBs and angiotensin receptor blockers
(ARBs) may be superior to other classes for preventing stroke
due to their strongest effects on reducing BPV (Fig 3).11 The
long-acting and lipophilic characteristics of antiHTNdrugsmay
contribute to this benefit.
On the other hand, diuretics – including an aldosterone
blocker and other new drugs such as an angiotensin receptor-
neprilysin inhibitor, LCZ696 (sacubitril/valsartan),56–59 and a
sodium-glucose co-transporter 2 (SGLT2) inhibitor, which
significantly reduce circulating volume – may be superior for
preventing HF,60 by their BP-lowering effect predominantly on
nocturnal BP (Fig 3).11 High nocturnal SBP increases the left
ventricular wall stress more than daytime BP does, because the
supineposition during sleep increases thepreload due to a fluid
shift from the lower body to the upper body.
Considering the higher salt intake of Asians and its direct
adverse effect,61 salt restriction and diuretics can be expected
to be especially effective in Asians.2 In a intervention study, a
3-month education program by nutritionists along with salt
restriction to ≤6 g per day (as recommended by the Japanese
Society of Hypertension)1 significantly lowered the 24-h
urinary sodium excretion and 24-h SBP in treated HTN
patients compared to the control group.62 In Japan, the most
commonly used classes of antiHTN drugs are CCBs, followed
by ARBs.63 It is important to choose a long-acting antiHTN
drug with a longer half-life, such as amlodipine.19 The
BP-lowering effect of a CCB is independent of salt sensitivity
and salt intake. Thus, a CCB is one of the most efficacious
antihypertensive drugs for Asian patients.64 In fact, in our
previous comparison study, amlodipine was superior to
valsartan, a short-acting ARB, for reducing the 24-h BP level
including morning BP in HTN patients.65 The Azilsartan
Circadian and Sleep Pressure – the First (ACS1) study, a
multicenter, randomized, open-label, two-parallel group
study demonstrated that amlodipine was superior to
azilsartan for reducing ambulatory BP in Japanese HTN
patients.66 This may be due in part to the greater salt intake
by Asians, because of increased circulating volume, resulting
in a reduction of the RAS activity.
A CCB lowers the higher baseline BP level more extensively
than other antiHTN drugs of different classes including RAS
inhibitors; however, a CCB does not reduce the low baseline
BP very much, resulting in the most effective lowering effect
of BPV among the different classes of antiHTN drugs. Thus, a
CCB seems to be the best choice for older patients with
structural HTN with increased BPV. On the other hand, a RAS
inhibitor would be preferable for younger metabolic HTN
patients with neurohumoral activation. Some international
guidelines concerning the management of HTN recommend
selecting different drugs depending on the patient's age, but
no studies have investigated the relationship between drugselection and age-related differences. In fact, the ACS1 study
demonstrated that azilsartan was superior to amlodipine for
achieving a successful BP control rate in younger HTN. The
post hoc analysis of the ACS1 study conducted to investigate
age- and sex-related differences in the antiHTN effects of
azilsartan and amlodipine revealed that azilsartan signifi-
cantly reduced diastolic BP in male patients <60 years old
compared to amlodipine, but amlodipine significantly reduced
SBP in female patients ≥60 years old compared to azilsartan.67
AntiHTN strategies considering these age- and sex-related
differences may increase cost-effectiveness in the long-term
management of HTN. Based on the above-described findings, a
RAS inhibitor may be preferable in the early stage of HTN for
younger adults with metabolic neurohumoral HTN, and a CCB
would be preferable in the later stage of HTN for older patients
with structural hypertension after their SBP has gradually
increased to an uncontrolled status.
Diuretics may be more effective in Asians who consume
higher amounts of salt than in Westerners who consume less
salt. A recent double-blind, randomized, comparative study of
diuretics in Indian HTN patients demonstrated that daily
treatment with low-dose chlorthalidone (6.25 mg) more
effectively reduced 24-h BP and nocturnal BP compared to
hydrochlorothiazide (12.5 mg).68 When combined with an
ARB, a small dose of a diuretic, i.e., 6.25-mg hydrochlorothiazide,
was effective in Japanese hypertensive patients with higher salt
intake and higher salt sensitivity.42
There is a difference in diurnal BP-lowering effects
between CCBs and diuretics. The use of a diuretic both as
monotherapy and in ARB–diuretic combination therapy is
more effective for reducing nocturnal BP, whereas the use of a
CCB is more effective for reducing higher daytime BP levels
and BPV.69 If BP is not well-controlled, the three-drug
combination of a RAS inhibitor, a CCB and a diuretic is the
gold standard for the treatment of uncontrolled HTN in both
Asians and Westerners.
Time of dosing
The bedtime dosing of antiHTN drugs is effective for morning
and nocturnal HTN. In our Japan Morning Surge-1 (JMS-1)
study, the bedtime dosing of doxazosin reduced morning BP
values and the urinary albumin/creatinine ratio (UACR), and
the reduction of the UACR was independent of the reduction
of BP.31 In the Japan Morning Surge-Target Organ Protection
(J-TOP) study, the bedtime dosing of candesartan was more
effective for reducing the UACR than morning dosing.70 In
RAS inhibitor combination therapy with a diuretic or CCB and
bedtime or morning dosing therapy, the reduction of noctur-
nal BP is critically important for reducing the UACR.19 In
the recent multicenter, prospective, randomized open-label,
ARB/CCB Longest Combination Treatment on Ambulatory and
Home Blood Pressure in Hypertension with Atrial Fibrillation:
Multicenter Study on Time Of Dosing (ACROBAT) study,71
which investigated the difference in the BP-lowering effect of
long-acting telmisartan/amlodipine combination tablets be-
tween morning and bedtime dosing in HTN with paroxysmal
atrial fibrillation, significant reductions were revealed in 24-h,
nighttime, and morning BP by ABPM and day-by-day home
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BP-lowering effects were similar regardless of the timing of
administration. The N-terminal of the prohormone BNP
(NT-proBNP) and UACR levels were significantly decreased
only in the bedtime dosing group.
Device treatment
A catheter-based renal denervation technique was recently
introduced for the management of drug-resistant HTN. The
SYMPLICITY HTN-1 and HTN-2 trials demonstrated a marked
office BP reduction by renal denervation, but the SYMPLICITY
HTN-3 controlled trial using a sham group demonstrated no
significant office BP-lowering effect by renal denervation
comparedwith a sham group.72We conducted the SYMPLICITY
HTN-Japan trial with Japanese patients with drug-resistant
HTN.73 In the SYMPLICITY HTN-Japan trial, the renal denerva-
tion arm tended to show more lowering of the 24-h SBP
compared to the control arm. However, the trial was stopped
because of the negative results of the SYMPLICITY HTN-3 trial.
In the analysis of the combined ABPM data of the SYMPLICITY
HTN-3 and HTN-Japan trials, renal denervation significantly
reducedmorning and nocturnal BP values, but it did not reduce
daytime BP.32 This can be partly explained by the close
association between morning HTN and increased sympathetic
activity. Nocturnal HTN is frequently observed in OSA patients,
who are likely to have increased sympathetic activity. The
SPYRAL HTN Global Trial is currently underway and is being
conducted to determine the 24-h BP-lowering effect of renal
denervation in theabsenceandpresenceof antiHTNmedication.74New concept of hemodynamic biomarker-initiated
‘anticipation medicine’
In the recent guidelines, the diagnosis and management of
HTN and the estimated risk of CVD are based on the average
of BP values in consideration of concomitant risk factors and
organ damage at a specific point of time. Beyond this current
guideline-based standardized management, there are two
perspectives on the ‘perfect individualized medicine aiming
at CVD event-zero’ (Fig 6). One is ‘precision medicine,’ which
is defined as an approach to disease treatment and preven-
tion that seeks to maximize effectiveness by taking into
account individual variability in genes, environment, and
lifestyle.75 This would be dramatically improved by powerful
methods such as the use of large-scale biologic databases
(e.g., the human genome sequence), proteomics, metabolo-
mics, genomics, diverse cellular assays, and mobile health
technology and computational tools for analyzing large sets
of data.
Anticipation medicine
Another perspective is ‘anticipation medicine,’ which is
defined as an approach to disease treatment and prevention
that predicts future risk by taking into account longitudinal
(time-domain) individual changes in markers and the status
of disease against environmental and behavioral factors. Oneof the most promising approaches to ‘perfect individualized
medicine’ is the combination of precision medicine and
anticipation medicine by an information and communica-
tions technology (ICT)-based approach using hemodynamic
biomarkers (i.e., the BP level and new the indexes of BP/heart
rate variability and baroreceptor sensitivity) with different
time-phases (Fig 6).
BP variability with different time-phase
Accumulating evidence indicates that independently of an
individual's average BP levels, increased BPV presents risks of
both CVD events and organ damage.36,76–89 BPV can be
examined in several time phases: orthostatic, beat-by-beat,
psychological or physical stress-induced, diurnal, day-by-day,
office or clinic visit-to-visit, seasonal, and yearly.36,76 Nearly
all of the BPV phenotypes correlatewith each other to some degree,
and nearly all have been reported to be CVD risk factors.90–93 These
varying forms of BPV can be examined by methods such as home,
office, and ABPMmeasurements (Fig 7).36,76
BPV is both a sensor of cardiovascular dysregulation that is
affected by an individual's characteristics, medication status,
and the many daily stressors of environmental conditions
and psychobehavioral factors, and a modifiable risk factor for
CVD and organ damage.94–98 BPV is thus considered a “master
biomarker” in the healthcare field.
The components of BPV may have different clinical
impacts on CVD. A long-term increase in the average of BP
values would be considered a chronic risk factor for advanc-
ing endothelial dysfunction and subsequent atherosclerosis,
whereas relatively short-term exaggerated BPV (e.g., the BP
surge) would be considered an acute risk factor which triggers
an atherothrombotic CVD event by a mechanical stress-
induced plaque rupture. These different roles of the risks
presented by BPV are similar to the risks of heart failure:
chronically advancing LVH, and the triggering of acute HF
afterload mismatch due to an abrupt increase in SBP. In
combination with the conventional prevention of chronic risk
factors, a real-time ICT-based acute CV risk prediction and alert
system would provide a new hemodynamic biomarker-
initiated way to prevent falling the cliffs to the onset, recurrence,
and severity of CVD events, resulting in a healthy life and
increased longevity (Fig 8).
The resonance hypothesis
We are now proposing the ‘resonance hypothesis’ of BPV.94,99
On the basis of reduced baroreceptor sensitivity and small-
artery remodeling according to aging, each type of BPV with
different time phases increases. The degree of increase in each
type of BPV may be different in different persons. When the
timing of each type of BPV wave with different time phases is
different, the total summation of BPV at each time phase is
small. However, the timing of all of the BPV waves with
different time phases is synchronized and resonance of the
pulse wave occurs, resulting in the generation of a critically
large dynamic BP surge that would trigger a CVD event (Fig 9).
For example, the morning BP surge is one of the several
types of BPV.36 The morning BP surge can be potentiated
Fig 6 – Cardiovascular disease ‘anticipation medicine.’ There are two perspectives on ‘perfect individualized medicine aiming
at cardiovascular event-zero.’ One is the precisionmedicine approach, and the other is anticipationmedicine. ICT, information
and communication technology.
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BPV, resulting in morning-onset CVD events.99 In ABPM
studies, the morning BP surge was exaggerated in the winter,
especially in elderly patients (the winter morning surge
in BP).100 The coexistence of exposure of airborne PM2.5 and
cold temperature may increase morning BP.98 These changes
in the morning BP surge may contribute to the increase in
CVD events in the winter among the elderly and on Mondays
among working adults.Fig 7 – ICT-based assessment of different blood pressure variabi
atherothrombotic syndrome (SHATS). ABPM, ambulatory blood p
information and communication technology. (Modified from Ref.Maximum SBP, one of the measures of day-by-day HBPM
most frequently observed in the morning (in approx. 2/3 of
observations), has been reported to be significantly associated
with measures of CV remodeling (i.e., the left ventricular mass
index and carotid intima-media thickness) even in HTN with a
well-controlled average of home BPs <135/85 mmHg.101 In
addition, the increased standard deviation of morning BP is a
significant independent predictor of CVD death.77 Thus, an
unstable morning BP surge synergistically augmented by thelity and vascular damage in systemic hemodynamic
ressure monitoring; BPM, blood pressure monitoring; ICT,
36).
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advance organ damage and trigger CVD events than a stable
and reproducible morning BP surge.
Systemic hemodynamic atherothrombotic syndrome (SHATS)
In 2013 we proposed a novel disease entity, systemic
hemodynamic atherothrombotic syndrome (SHATS), which
is also a risk factor for CVD events and organ damage
(Fig 10).2,19,36,102,103 Characterized by a vicious cycle between
vascular disease and hemodynamic stress (based on BPV,
the pulse wave form and blood flow variability), the presence
of SHATS enhances the effects of BPV on peripheral organ
damage and subsequent CVD events. A novel aspect of
SHATS is its synergistic consideration of hemodynamic
stress and the numerous types of BPV in relation to vascular
disease. In addition, the standing test, HBPM, ABPM and other
currently available methods can be used to detect the pheno-
types of BPV in SHATS.
Large-artery disease and other types of vascular disease
increase the impact of exaggerated BPV on CVD events. TheFig 8 – Differential roles of acute vs chronic hemodynamic bioma
in the early vs late stages. By analysis of variability of hemodynam
and individual characteristics, new hemodynamic biomarkers would
disease andasacute risk factor triggering cardiovascular events. The r
would achieve the newhemodynamic biomarker-initiated prevention
for longevity. ABPM, ambulatory blood pressuremonitoring; CKD, ch
pressuremonitoring; ICT, information and communication technologtriggering of CVD events and organ damage at peripheral
atherosclerotic sites often follows an increase in large-artery
stiffness, as such stiffness decreases the attenuation of pulses
that are transmitted to the peripheral arteries. Even in
patients without atherosclerosis in large artery, the next
specific target of SHATS is strain vessels (small arteries of the
brain, heart, kidney, and eyes), resulting in small-vessel
diseases.104 SHATS may also increase the risk of HF through
an increase in the circulating volume due to baroreflex
failure105 and via an increase in the peak and variability of
the afterload. In individuals with SHATS, synergistic
resonance among the morning BP surge and different types
of BPV may occur, and this could easily trigger CVD events in
the morning.
The underlyingmechanism of SHATS is thought to include
impairments of vascular and neural components of the
baroreflex caused by increased central sympathetic activity
and decreased carotid dispensability, respectively. Increases
in BPV are often due in part to small-artery remodeling as well
as large-artery disease. Indeed, the three BP measures of
SHATS are increased BPV, impaired baroreceptor sensitivity,rker-initiated anticipation medicine of cardiovascular disease
ic parameters in combination with environmental conditions
be generated separately as chronic risk factor advancing vascular
eal-time ICT-based cardiovascular riskpredictionandalert system
of falling the cliff of cardiovascular events resulting in healthy life
ronic kidney disease; CV, cardiovascular; HBPM, home blood
y.
Fig 9 – Synergistic resonance hypothesis of blood pressure variability. ABPM, ambulatory blood pressure monitoring; BPM,
blood pressure monitoring; CV, cardiovascular; BRS, baroreceptor sensitivity (Modified from Ref. 99).
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The different phenotypes of BPV may be determined by the
extent of peripheral and central neurohumoral activation and
the cardiovascular reactivity in each specific condition.
The measurements of ambulatory BP, including the morn-
ing BP surge, reflect an individual's pulsatile hemodynamics as
influenced by arterial stiffness and wave reflections, and two
important components of pulsatile hemodynamics are arterial
stiffness and pressure wave reflections. The concept of SHATS
underscores that clinicians should recognize the synergisticFig 10 – Concept of systemic hemodynamic atherothrombotic syn
the riskof organdamageand cardiovascular events via avicious cycl
index; ECG, electrocardiography; BNP, B-type natriuretic peptide; NT
ratio, PWV, pulse wave velocity; CAVI, cardio-ankle vascular index;
(Modified from Ref. 93).risk posed by exaggerated BPV and vascular damage in clinical
practice.
We are now conducting the prospective CardiOVascUlar
Prognostic Coupling (COUPLING) study to investigate the
serial interaction of subclinical CVD and vascular disease
and its impact on CV prognosis in approx. 5000 patients with
one or more risk factors, using a device (from Fukuda Denshi,
Co. Ltd.) that simultaneously assesses electrocardiograph and
vascular properties such as the cardio-ankle vascular index
(CAVI) since 2015. The CAVI is correlated with the stiffnessdrome (SHATS). SHATS is a disease condition that accelerates
eofhemodynamic stress andvascular disease.AI, augmentation
-ProBNP, N-Terminal-ProBNP; UACR, urinary albumin/creatinine
ABI, ankle-brachial index; FMD, flow-mediated dilatation
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of the CAVI in evaluations of integrated arterial stiffness
including that of the central aorta.106The disaster cardiovascular prevention (DCAP)
network – an ICT-based model
The next stage of the management of HTN is information and
communication technology (ICT)-based approaches using
HBPM. ICT-based HBPM per se improved the home BP control
status even in remote geographic locations.107 The graphic
function of an ICT-based approach that demonstrates the
trend of BP control status also helps to achieve faster home BP
control.108 Various types of BPV with different time phases
can be detected by ICT-based monitoring, and the synergistic
assessment of BPV in combination with a vascular evaluation
will lead to more precise risk assessments of SHATS (Fig 7).
We developed an ICT-based BP monitoring system at the
time of the Great East Japan earthquake (March 2011) to
improve the BP control in people who had been affected by
this disaster. A major disaster increases the thrombophilic
tendency and BP values, both of which trigger disaster-
induced CVD events such as stroke and cardiac events.109–111
At the time of the Great Hanshin-Awaji earthquake (January
1995), I worked for the Awaji-Hokudan public clinic in areas
near the earthquake's epicenter, and I observed the disaster-
associated increase in BP.109 Most of the HTN patients
developed uncontrolled HTN, but their BP levels returned to
the previous BP level within 1 month after the earthquake.
However, some patients (especially those with CKD) devel-
oped persistent uncontrolled disaster HTN.109,112
At the time of Great East Japan earthquake, we established
the web-based disaster cardiovascular prevention (DCAP)
network (which provided a DCAP risk and prevention score
assessment and self-measured BP monitoring) for survivors
of the 2011 earthquake.113 The DCAP network system used
cloud computing on the Internet to monitor the individual BP
data self-measured at home or at a shelter, and this system
was first introduced to a shelter in one of the most damaged
areas (Minami Sanriku).113 It had been shown that
disaster-induced increases in BP are affected by the increased
white-coat effect (clinic BP minus home BP), and thus the BP
measurement by an unknown medical volunteers under
stressful conditions in a shelter may tend to result in
overestimations; self-measured BP could therefore be consid-
ered for obtaining more accurate BP values under such
conditions.111,113 In most patients affected by a disaster, the
increases in clinic BP and self-measured BP are transient, and
the BP levels return to the pre-disaster baseline levels within
4 weeks.109–111 Thus, it is recommended that the BP levels of
individuals who are affected by a disaster should be moni-
tored ideally by self-measured BP in the disaster shelter or at
home, and the dose of antiHTN medication should be
reconsidered every 2 weeks during the short-term period
after the disaster situation.
The pressor effect observed after the 2011 East Japan Earth-
quake lasted far longer than that following the Hanshin-Awaji
Earthquake in 1995, most likely due to the greater damage andsequelae of the three disasters in 2011 (i.e., the earthquake, the
subsequent tsunami, and the radiation exposure from the
Fukushima Daiichi nuclear disaster). Twenty-one months after
the East Japan Earthquake, on December 7, 2012, the largest
aftershock occurred and tsunami warnings sounded. An ABPM
study of eight patients who lived in the disaster area was being
conducted at that time, and it revealed a pressor effect followed by
increased nocturnal and morning BP levels.114 In addition, the
nocturnal andmorning BP values were significantly greater in the
subjects who were staying in temporary housing compared to the
subjects who continued to live in their own homes. The more
difficult living conditions in the temporary housing after the
disasterwere likely tohave been stressful, contributing to a greater
risk of CVD events.
Minami Sanriku study
We have continued to monitor home BP using the DCAP
system in approx. 350 outpatients of Minami Sanriku Hospital
with Dr. Masafumi Nishizawa (the hospital’s vice president)
for over 5 years. After the 2011 earthquake, the outpatients'
home BP levels gradually decreased and reached approx.
<125 mmHg (Nishizawa, Hoshide, Kario et al., unpubl. data),
resulting in an approx. 50% reduction of CVD events in this
geographic area. The successful use of the DCAP network in
the Minami Sanriku area validates our introduction of an
ICT-based home BP-guided approach with the goal of reduc-
ing the incidence of CVD events. In the Minami Sanriku study,
we have also followed the 24-h ambulatory BP twice-yearly
(summer and winter) since the winter of 2012 toward the goal
of achieving ‘perfect 24-h BP control.’Research and development of new BP monitoring
When using an ICT-based hemodynamic biomarker-initiated
CVD prevention, the development of BP monitoring devices
that can detect different types of hemodynamic stress on the
CV system is important.Wehave beendeveloping the following
new ABPM and HBPM devices.
Home-activity-ICT-based ABPM (HAI-ABPM)
We have conducted the JMU-ABPM Study, Wave 1 at the
Awaji-Hokudan Public Clinic since 1992,22,30,33,45,46 and we
began the Japan Ambulatory Blood Pressure Prospective study
(JAMP) in 2009. The JAMP study is an ongoing prospective
nationwide study using ABPM in approx. 7000 Japanese
patients with one or more CVD risk factors. We developed a
new IT-based home and ABPM device equipped with (1)
high-sensitive actigraphy that can detect fine-scale physical
movements in three directions, (2) a thermometer, and (3) a
barometer (i.e., Home-activity-ICT-based ABPM [HAI-ABPM],
A&D Co.Itd, Tokyo).
As ambulatory BP is partly determined by an individual's
physical activity, this device automatically calculates two
new indices, ‘BP reactivity,’ based on the slope of ambulatory
BP increase against activity just before the BP measurement
(actisensitivity),19,34,115 and based on the slope of cold
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have introduced the concepts of ‘trigger-induced BP reactivity
index’ to identify specific high-risk patients as those with
‘thermosensitive HTN’ and ‘actisensitive HTN,’ respectively.
This device can monitor both home and ambulatory BPs and
send the data by ICT, and we are now starting a new nationwide
cohort using this device, theHAI-JAMP (Home-Activity ICT-based
Japan AMbulatory Blood Pressure Prospective) study.
Home nocturnal BP monitoring
Basic home nocturnal BPmonitoring (Medinote→HEM-7252G-HP)
ABPM had once been the only availablemethod for measuring
a subject's nocturnal BP during his or her sleep, and as an
alternative to ABPM, our development of the Medinote
semi-automatic nocturnal HBPM device was a first step in
obtaining basic nocturnal BP data. The Medinote (Omron
Healthcare, Kyoto, Japan) measures the user's BP values
automatically at fixed intervals while he or she sleeps.2,19
The user simply places the Medinote's cuff on his or her arm
just before going to bed. The user's BP data are stored in the
device's memory file. The Japan Morning Surge Home Blood
Pressure (J-HOP) study, a nationwide cohort study, was the
first investigation to use the Medinote on a large scale.63,116,117
The design for HBPM devices has already advanced to a new
ICT-based nocturnal BP monitoring device, the HEM-7252G-HP
(Omron).
In the J-HOP study, we recruited 4310 patients who had one
or more CVD risk factors. The results of this study demon-
strated that morning BP and evening BP provide equally
useful information regarding subclinical target organ damage,
yetmultivariatemodeling highlighted the stand-alone predictive
ability of morning BP.63 We successfully measured the nocturnal
home BP of 2562 participants using the Medinote monitoring
device three times during sleep (at 2:00, 3:00, and 4:00 a.m.) as
well as three times each in themorning and evening for 14 days.
The 4:00 a.m. SBP levels were slightly but significantly higher
than those at the other two time points, by 1.5 mmHg
(p < 0.0001), but there were no significant differences between
the nocturnal home SBP levels at 2:00 and 3:00 a.m. Based on the
J-HOP results, we concluded that it is feasible to have subjects
self-measure their nocturnal BP at home.117. In our J-HOP
sub-analysis, the nocturnal home BP values obtained were
almost the same as those of nocturnal BP values obtained by
ABPM.116 In the J-HOP Study, the subjects' nocturnal home SBP
was significantly correlated with measures of organ damage.117
Twenty-seven percent of the subjects whose morning home BP
was well-controlled at <135/85 mmHg showed masked home
nocturnal HTNwith nocturnal home SBP ≥120 mmHg, and these
subjects also had higher NT-proBNP and UACR values.117
Nocturnal home BP was also a better indicator of BP control
during antiHTN treatment. In our Japan Morning Surge-Target
Organ Protection (J-TOP) study, cardiac echography and electro-
cardiography revealed that the reduction of nocturnal home BP
was more closely associated with the regression of left ventric-
ular hypertrophy (LVH). The J-TOP findings indicate that remain-
ing uncontrolled nocturnal HTN should be a focus of future
antiHTN treatment even after a patient's morning BP is
well-controlled by conventional home BP-guided treatment.‘ThermosensitiveHTN’ – Detecting home BP device
The HEM-7252G-HP includes a thermosensor within the
device. BP is partly associated with temperature. Themorning
BP level in particular is closely determined by cold tempera-
tures, especially in the elderly. However, this characteristic
varies among different HTN patients. Here I first used the
term ‘thermosensitive HTN’19,36 to define HTN in which home
BP is affected by seasonal temperature changes (e.g., R2 > 0.3,
change of morning SBP >10 mmHg/10 °C).19 Individuals with
thermosensitive HTN may experience a ‘winter morning
surge in BP’100 that contributes to an increased rate of CVD
events during the winter season. We are now conducting the
Prediction of IT-Home BP Variability (PREDICT) study using
ICT-based monitoring to examine the possibility of the
prediction of near-future home BP values at the individual
level based on the patient's characteristics, environmental
conditions, and past day-by-day home BP values.
ICT-based triggering of home nocturnal BP monitoring (ITNP)
‘Triggered BP measurement’ in HBPM is a concept that we
introduced in 2015.19 The measurement of BP at a trigger
signal based on specific conditions was not provided by any
HBPM device prior to that time. The benefit of triggered BP
measurement at home is that it can be used to repeatedly
measure a subject's specific BP levels and BPV related to risky
conditions. We hypothesized that since repeated measure-
ments can be obtained by HBPM, repeated BP measurements
taken at triggered conditions at home could improve the
detection of abnormal BP peaks in specific conditions that are
CVD risk-related.
In our development of triggered BP measurement, we
devised a ‘trigger nocturnal BP monitoring (TNP)’ method
based on the Medinote's automated fixed-interval measure-
ments, with an added trigger function. With a pre-set
threshold for oxygen desaturation (which is continuously
monitored by pulse oximetry), the HBPM device is triggered to
initiate BP measurements when the wearer's oxygen
desaturation falls below the threshold.2,19,103,118,119 OSA pa-
tients' nocturnal BP profile is characterized by increased
nocturnal BPV, nocturnal HTN with the non-dipper/riser
pattern, and exaggerated morning BP surges.43 The higher
nocturnal BP that is directly linked to OSA episodes could not
be detected by earlier HBPM and ABPM methods, but the TNP
method can successfully detect the OSA-specific exaggerated
nocturnal BP surges triggered by hypoxic episodes (Fig 11).118
Compared to the general population, OSA patients also
experience sleep-onset CVD events more frequently during
sleep, and their exaggerated nocturnal BP surges may partly
explain this.119
We also added a trigger function to the Medinote to detect
the ‘basal BP,’ which is based on the wearer's lowest heart rate.
The basal BP, defined as the nocturnal BP values obtained after
the signal triggered by the lowest heart rate during sleep
(Fig 11),2,19 is the nocturnal BP with the lowest sympathetic
drive. The basal BP is determined based mainly on the
circulating blood volume and structure of the vasculature.
Nocturnal HTN has shown heterogeneous pathophysiology.
Two typesofnocturnal BPwithdifferent clinical implications (i.e.,
cardiovascular structure-determined basal BP and sympathetic
Fig 11 – Definition of nocturnal blood pressure parameters
obtained by trigger nocturnal blood pressure monitoring
(TNP). SBP, systolic blood pressure (Modified from Ref. 44).
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measures the double-trigger signals of hypoxia and heart rate.
TNPmonitoring may thus help achieve more effective control of
nocturnal HTN with a different pressor mechanism by identify-
ing the best class of antiHTN drugs. Nocturnal BP values with
these different pressor mechanisms cannot be differentiated by
conventional ABPM using fixed-interval measurements.
With our colleagues at Omron Healthcare, we developed
an ICT-based TNP (ITNP) system (Fig 12)103 that is a cloud
computing-based composite analysis and management sys-
tem using data sent from the BP device worn by a patient at
home. Repeated and day-by-day variabilities in nocturnal BP
are detected by the ITNP system, as are the basal nocturnal BP
and morning BP values and the nocturnal BP surges linked to
OSA episodes, the extent of which is often affected by daily
environmental changes. In 2012 we began a prospective
investigation using this ITNP system, the Sleep Pressure and
Disordered Breathing in Resistant Hypertension and Cardio-
vascular Disease (SPREAD) study, to determine the clinical
implications of nocturnal BP and nocturnal BP surges in
high-risk patients with resistant HTN and/or CVD. Improved
sensitivity for the diagnoses of OSA and the related nocturnal
BP surge can be achieved based on repeated assessments
using the ITNP system in real-life settings. The presence or
severity of OSA could be missed or underestimated, respec-
tively, by single-day polysomnography in alcohol-prohibited
conditions in hospitals. Individuals with moderate OSA may
thus not be identified in such conditions. In the SPREAD study,
the degree of apnea/hypopnea episodes among the subjects who
had mild-to-moderate OSA showed significant night-by-night
variability, and on alcohol-intake days the nocturnal BP values
and nocturnal BP surges of these subjects were increased.19
The ITNP systemcan also evaluate the efficacy of treatment.
In our study of TNP, the bedtime dosing of nifedipine and
carvedilol significantly reduced all of themeasures of nocturnal
BP, although the nocturnal BP-lowering properties of these two
drugs are different. 44 Compared with nifedipine, carvedilol
comparably reduced the peak nocturnal BP, while it significantly
but less extensively reduced basal BP, resulting in a significant
suppression of hypoxia-induced nocturnal BP surges.44 In
addition, the ITNP system was able to evaluate the efficacy of
continuous positive airway pressure (CPAP). Effective CPAP
reduces nocturnal SBP markedly greater when evaluated by
measuring the hypoxia-peak nocturnal SBP.19
The detection of high-risk OSA patients with nocturnal
HTN and/or a nocturnal BP surge will be improved by the use
of the ITNP system. In addition, better BP control could be
achieved in OSA patients who are using a CPAP and those
who are under antiHTN treatment when the ITNP system is
used. The development of organ damage and CVD events in
OSA patients would be effectively suppressed by strict 24-h BP
control (including these patients' hypoxia-induced peaks
and nocturnal BP), and using the ITNP system will help
reach this goal.
Beat by beat wearable ‘surge' BP monitoring
Wearable noninvasive beat-by-beat BP monitoring has been
the dream of doctors who manage HTN. A recent systematicreview comparing continuous noninvasive arterial BP moni-
toring with invasive arterial BP monitoring demonstrated that
the inaccuracy and imprecision of continuous noninvasive
arterial BP monitoring devices are larger than what was
defined as acceptable.120 There are twomethods that could be
used for noninvasive continuous beat-by-beat BP monitoring.
One is the applanation tonometry method, and the other is
the pulse wave transit time (PWTT) method. There are several
limitations of these methods.
The PWTT-method does not take direct measurements; it
provides an indirect estimation of arteria BP or cardiac
output.121 However, the biggest problem with the PWTT
method is that the PWTT is determined by the functional
stiffness and the structural stiffness, and the impacts of
functional versus structural components which determine
the PWTT differ among individual patients. The PWTT
method may be used for younger subjects whose arteries are
soft, because the PWTT is predominantly determined by the
intra-arterial BP and the PWTT could change very much
according to the change in intra-arterial BP. However, in
high-risk patients with stiffened arteries, the PWTT is
predominantly determined by the structure of the stiffened
arteries, and the PWTT should change little with changes in
intra-arterial BP. Thus, the estimated BP values may be
relatively accurate for healthy younger patients at the early
stage of HTN without vascular disease, but the estimated BP
values would likely be inadequate for high-risk patients with
advanced vascular disease. In addition, theoretically, the
change in the PWTTmay not reflect the beat-by-beat changes
in intra-arterial BP, because the PWTTmethod uses the mean
pressure to estimate BP.
The applanation tonometry method provides direct mea-
surements based on the law of Laplas. Effective applanation
of the arterial wall is required to achieve accurate results. The
radial artery is the best artery for effective applanation,
because it is shallow beneath the skin and is fixed on a radial
bone. However, for effective applanation, the position of the
pressure sensor should be fixed exactly and stably without
physical movement during measurement. A single sensor
structure type (pencil-type) is used by the SphygmoCor®
Fig 12 – ICT-based trigger nocturnal home BPmonitoring systemwith oxygen and heart rate triggers and a cloud system (ITNP,
2015, developed by Jichi Medical University, Tochigi, and Omron Healthcare Inc., Kyoto, Japan). (Modified from Ref. 103).
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pulse wave form, and this requires a skilled operator to obtain
the accurate pulse wave form.122
In contrast, an arrayed sensor, once set on the subject's
wrist, is servo-controlled to optimize the hold-down pressure
in order to attain effective applanation of the artery andFig 13 – Nocturnal bloodpressure surges detected bywearable “surg
hypertensive patients with sleep apnea. BP = blood pressure, PSG =automatically select a sensor element outputting the highest-
quality tonometric waveform. The accuracy of this blood
pressure monitoring device (the JENTOW) is described
elsewhere.123 It is expected to enable ambulatory arterial
tonometry. However, the weaknesses of a tonometry BP
monitoring device are that (1) the position of the sensor toe”bloodpressuremonitoring ofwrist-type tonometry (WSP) in a
polysomnography.
Fig 14 – Hemodynamic biomarker-initiated ‘anticipationmedication’ for the prevention of onset and aggravation of cardiovascular
events. CKD, chronic kidney disease; ECG, electrocardiography; Echo, cardiac and carotid echography; PWV, pulse wave velocity;
CAVI, cardio-ankle vascular index; ABI, ankle-brachial index.
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movement of the wrist, which disturb effective applanation,
are frequent. There is also an inconstant positional relation-
ship between the heart and the measurement site, which
would introduce the influence of hydrostatic pressure alter-
ations on the BP level.
Omron Healthcare Inc. recently publicized a prototype of a
wearable wrist type of tonometry BP monitor that uses recent
advances in automatically-controlled technology.
This prototype has two tonometery sensor plates and the
angle of the arrayed sensor plate to cover the radial artery is
automatically adjusted in order to obtain effective applanation.
We are testing this device and improving it in collabora-
tion with Omron with the goal of developing more accurate
beat-by-beat ‘wearable surge BP monitoring (WSP),' which
could measure the absolute values of the maximum peaks of
beat-by-beat pressure (Fig 13).Perspectives
BPV is an important measure of both ‘precision medicine’ and
‘anticipation medicine’ for CVD. Repeated exaggerated BPV
triggered by specific conditions may advance organ damage,
and one extremely large dynamic BP surge generated by the
synergistic resonance of various BP surges with different time
phases may trigger a cardiovascular event. Thus, in the
future, the ‘ICT-based 24-h anticipation management of
HTN’ in consideration of BPV and nocturnal HTN is a
promising individualized approach against advancing athero-
sclerosis from early stages and against the triggering of CVD
events at the final stage of CVcontinuum among high-risk
patients. However, intermittent BP measurements at fixed
intervals would underestimate the CVD risk of BPV andexaggerated BP surges. Finally, the advances in wearable
‘beat-by beat’ continuous BP monitoring and ICT-based
real-time large-scale data resonance analyses and simulta-
neous feedback systems (Fig 14) will achieve a paradigm shift
from ‘dots’ of BP management to ‘seamless’ event anticipa-
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